| S-adenosyl methionine ( Premium SAMe UHI ™): |
|
UHI’s physicians and pharmacologists created Premium SAMe UHI™ using
the principles of evidence based medicine (EBM) and the resULTs of university clinical trials worldwide. |
|
Evidence based medicine researchers evaluate a broad spectrum of research material—such as
meta-analyses, systematic reviews of existing research, randomized controlled trials, cohort
studies, and other methods of inquiry—to make decisions about patient care and treatment. |
|
Below is a cross section of the extensive scientific evidence used in formulating patent-pending
Premium SAMe UHI™ : |
|
S-adenosyl methionine |
|
In a double-blind crossover trial, the authors concluded that
S-adenosyl methionine is as
effective as celecoxib (Celebrex®) in the management of symptoms of knee osteoarthritis
(Najm WI et al, 2004). |
|
A meta-analysis concluded that S-adenosyl methionine appears to be as effective as NSAIDS in reducing
pain and improving the functional limitation in patients with osteoarthritis without the adverse
effects often associated with NSAID therapies (Soeken et al, 2003). |
|
S-adenosyl methionine plays an important role in the liver, acting as a protective agent
for oxidative stress. Patients with liver disease often become deficient and may benefit
from the administration of this supernutrient (Liber, 2002). |
|
A meta-analysis concluded that the efficacy of S-adenosyl methionine was equivalent to tricyclic
antidepressants with fewer side effects (Bressa, 1994). Another meta-analysis concluded that there
appears to be a role for this compound in the treatment of major depression in adULTs
(Williams et al, 2005). |
|
A double-blind, placebo controlled study found that S-adenosyl methionine was effective in treating
the pain, stiffness, fatigue, and mood of people suffering from fibromyalgia (Jacobsen et al, 1991).
|
|
|
|
Efficacy equal to NSAIDS such as celecoxib (Celebrex®) in the treatment of Arthritis: |
|
In a double-blind crossover trial comparing celecoxib (Celebrex®) with S-adenosyl methionine, the authors concluded that S-adenosyl methionine is as effective as celecoxib (Celebrex®) in the management of symptoms of knee osteoarthritis (Najm et al, 2004). A meta-analysis on the use of S-adenosyl methionine in osteoarthritis concluded that it appears to be as effective as NSAIDS in reducing pain and improving the functional limitation in patients with osteoarthritis without the adverse effects often associated with NSAID therapies (Soeren et al, 2002). |
|
Has potential protective effects on the liver: |
|
S-adenosyl methionine plays an important role in the liver, acting as a protective agent for oxidative stress. Patients with liver disease often become deficient in S-adenosyl methionine and may benefit from the administration of this supernutrient (Liber, 2002). |
|
Helps regulate mood and has efficacy in the treatment of depression: |
|
A meta-analysis on the use of S-adenosyl methionine in the treatment of depression concluded that its efficacy of was equivalent to tricyclic antidepressants with fewer side effects (Bressa, 1994). Another meta-analysis on the use of S-adenosyl methionine concluded that there appears to be a role for S-adenosyl methionine in the treatment of major depression in adULTs (Williams et al, 2005). |
|
Helps relieve the pain, stiffness, and fatigue associated with fibromyalgia: |
|
A double-blind, placebo controlled study found that S-adenosyl methionine was effective in treating the pain, stiffness, fatigue, and mood of people suffering from fibromyalgia (Jacobsen et al, 1991). |
| |
Devil's claw extract Harpagophytum procumbens: |
 |
| Premium SAMe UHI ™ Mechanism of Action
|
|
S-adenosyl methionine is a natural metabolite present in all living cells. It is formed from methionine,
an essential amino acid, and adenosine triphosphate. Evidence on Premium SAMe UHI™ suggests that it may
play a role in reducing inflammation, increasing proteoglycan synthesis, or creating an analgesic effect
(Najm et al 2004). Its antidepressive effects may resULT from increased production of neurotransmitters
such as serotonin, dopamine, and norepinephrine (Williams et al, 2005).
|
|
Arthritis: |
|
Arthritis is one of the most common conditions encountered with old age. Osteoarthritis (OA) is the most common form of arthritis and most frequently involves the knee joint. OA is characterized by the degeneration of articular cartilage. Symptoms can include pain, stiffness, and decreased range of motion. |
|
Currently, nonsteroidal anti-inflammatory drugs (NSAIDs) are the mainstay of treatment for arthritic pain. Each year in the United States, more than 100,000 people are hospitalized for gastrointestinal complications of NSAIDs, and of those, 15% die from these complications (Singh, 1999). |
|
S-adenosyl methionine (Premium SAMe UHI™): |
|
S-adenosyl methionine is a natural metabolite present in all living cells. It is formed from methionine, an essential amino acid, and adenosine triphosphate. Evidence on Premium SAMe UHI™ suggests that it may play a role in reducing inflammation, increasing proteoglycan synthesis, or creating an analgesic effect (Najm et al 2004). Its antidepressive effects may resULT from increased production of neurotransmitters such as serotonin, dopamine, and norepinephrine (Williams et al, 2005). |
| |
Premium SAMe UHI ™ Safety and Side Effects |
|
|
Side Effects:
|
|
S-adenosyl methionine has few reported side effects. Side effects may include occasional
gastrointestinal disturbances, mainly diarrhea (Morelli, 2003). |
|
ConsULT a physician if you experience any side effects. |
|
Discontinue use if an allergic reaction occurs. |
|
ConsULT a physician if you are using this product longer than six months. |
|
Contraindications: |
|
Use this product in consULTation with a physician if you have a history of depression,
bipolar disorder, or other psychiatric illnesses.
|
|
Drug interactions: |
|
No drug interactions have been reported for S-adenosyl methionine (Setty et al, 2005)
|
| |
| References: |
|
|
Curtis CL, Harwood JL, Dent CD, Caterson B. Biological basis for benefit of
nutraceutical supplementation in arthritis. Drug Discovery Today. 2004;9:16572.
|
|
Bressa GM. S-adenosyl-l-methionine as antidepressants: meta-analysis of clinical studies.
Acta Neurol Scand Suppl. 1994;154: 7-14.
|
|
Najm WI, Reinsch S, Hoehler F, Tobis JS, Harvery PW. S-adenosyl methionine (SAMe)
versus celecoxib for the treatment of osteoarthritis symptoms: a double-blind cross-over
trial. BMC Musculoskelet Disord. 2004 Feb 26;5(1):6.
|
|
Liber CS. S-adenosyl-l-methionine: its role in the treatment of liver disorders.
AM J Clin Nutr. 2002;76(5):1183s-7s.
|
|
Singh G, Triadalfilopolous G. Epidemiology of NSAID induced GI complications. J Rheumatol. 26:18-24.
|
|
Fiebich Bl, Heinrich M, Hiller K, Kammerer N. Inhibition of TNFalpha synthesis in
LPS-stimulated primary human monocytes by Harpagophytum extract SteiHap 69. Phytomedicine. 2001; 8:28-30.
|
|
Setty AR, Sigal LH. Herbal Medications Commonly Used in the Practice of Rheumatology:
Mechanisms of Action, Efficacy, and Side Effects. Semin Arthritis Rheum. 2005 Jun;34(6):773-84.
|
|
Jacobsen S., Dannekiold-Samsoe B, Andersen RB. Oral S-adenosylmethionine in primary fibromyalgia.
Double-blind clinical evaluation. Scandinavian Journal of Rheumatology. 1991;20(4):294-302.
|
|
Williams Al, Girard C, Jui D, Sabrina A, Katz DL. S-adenosylmethionine (SAMe) as treatment for
depression: a systematic review. Clinical & Investigative Medicine – Medecine Clinique et
Experimentale. 2005 June;28(3) 132-9. |
|
Soeken KL, Lee W, Bausell R, Agelli M, Berman BM. Safety and efficacy of S-adenosylmethionine
for osteoarthritis. ACP J Club. 2003 Jan-Feb;138(1):21.
|
|
| |
go BACK to PRODUCTS |
|
|
